Table 2.
Recommended Pneumococcal Vaccination Options for People With HIVa
| Vaccination history | Option A | Option B | Notes |
|---|---|---|---|
| Patients aged <65 y | |||
| Unvaccinated | PCV20 | PCV15 + PPSV23 8 wk later | — |
| PPSV23 only | PCV20 at ≥1 y | PCV15 at ≥1 y | — |
| PCV13 only | PCV20 at ≥1 y | PPSV23 at ≥8 wk, repeat PPSV23 at ≥5 y |
Review pneumococcal recommendations at age 65 y |
| PCV13 + PPSV23 | PCV20 at ≥5 y | PPSV23 at ≥5 y | Review pneumococcal recommendations at age 65 y |
| PCV13 + PPSV23 (2 doses) | PCV20 at ≥5 y | None | Review pneumococcal recommendations at age 65 y |
| Patients aged 65 y and older | |||
| Unvaccinated | PCV20 | PCV15 + PPSV23 8 wk later | — |
| PPSV23 only | PCV20 at ≥1 y | PCV15 at ≥1 y | — |
| PCV13 only | PCV20 at ≥1 y | PPSV23 at ≥1 y | — |
| PCV13 + PPSV23 at <65 y | PCV20 at ≥5 y | PPSV23 at ≥5 y | — |
a
Option A and Option B are both approved and available for use, depending on insurance coverage and availability of vaccines.
Abbreviations: PCV13, pneumococcal conjugate vaccine (protects against 13 serotypes); PCV15, pneumococcal conjugate vaccine (protects against 15 serotypes); PCV20, pneumococcal conjugate vaccine (protects against 20 serotypes); PPSV23, pneumococcal polysaccharide vaccine (protects against 23 serotypes).